Alzamend Neuro, Inc. (ALZN) NASDAQ

2.33

-0.01(-0.43%)

Updated at October 23 04:00PM

Currency In USD

Alzamend Neuro, Inc.

Address

3500 Lenox Road NE

Atlanta, GA 30326

United States of America

Phone

844 722 6333

Sector

Healthcare

Industry

Biotechnology

Employees

4

First IPO Date

June 15, 2021

Key Executives

NameTitlePayYear Born
Mr. Stephan JackmanChief Executive Officer & Director443,6171977
Mr. Milton Charles Ault IIIFounder & Vice Chairman8,3331970
Mr. Henry C. W. Nisser Esq.Executive Vice President, General Counsel & Director50,0001969
Mr. David J. KatzoffChief Financial Officer150,0001963
Mr. Kenneth S. Cragun CPASenior Vice President of Finance01961

Description

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.